AMARIN CORP PLC\UK Operating Lease, Expense
AMARIN CORP PLC\UK (AMRN) reported Operating Lease, Expense of $700.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-07-29
- AMARIN CORP PLC\UK operating lease, expense for the quarter ending 2026-06-30 was $700.00K, a 22.22% decline year-over-year.
- AMARIN CORP PLC\UK operating lease, expense for the quarter ending 2026-03-31 was $700.00K, a 12.50% decline year-over-year.
- AMARIN CORP PLC\UK operating lease, expense for the quarter ending 2025-12-31 was $100.00K, a 50.00% decline year-over-year.
- AMARIN CORP PLC\UK operating lease, expense for the quarter ending 2025-09-30 was $800.00K, a 0.00% change year-over-year.
- AMARIN CORP PLC\UK operating lease, expense for fiscal 2025 was $2.70M, a 6.90% decline from fiscal 2024.
- AMARIN CORP PLC\UK operating lease, expense for fiscal 2024 was $2.90M, a 9.38% decline from fiscal 2023.
- AMARIN CORP PLC\UK operating lease, expense for fiscal 2023 was $3.20M, a 14.29% increase from fiscal 2022.
- AMARIN CORP PLC\UK operating lease, expense for fiscal 2022 was $2.80M, a 27.27% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 6 month as first filed | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $700.00K 10-Q · filed 2026-07-29 | $1.30M 10-Q · filed 2026-07-29 | $1.50M derived: sum of 3 quarters · filed 2026-07-29 | $2.30M derived: sum of 4 quarters · filed 2026-07-29 | |||
| 2026-03-31 | $700.00K 10-Q · filed 2026-04-29 | $800.00K derived: sum of 2 quarters · filed 2026-04-29 | $1.60M derived: sum of 3 quarters · filed 2026-04-29 | $2.50M derived: sum of 4 quarters · filed 2026-07-29 | |||
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $900.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.80M derived: sum of 3 quarters · filed 2026-07-29 | $2.70M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $800.00K 10-Q · filed 2025-10-29 | $1.70M derived: sum of 2 quarters · filed 2026-07-29 | $2.60M 10-Q · filed 2025-10-29 | $2.70M derived: sum of 4 quarters · filed 2026-07-29 | |||
| 2025-06-30 | $900.00K 10-Q · filed 2026-07-29 | $1.80M 10-Q · filed 2026-07-29 | $1.90M derived: sum of 3 quarters · filed 2026-07-29 | $2.70M derived: sum of 4 quarters · filed 2026-07-29 | |||
| 2025-03-31 | $800.00K 10-Q · filed 2026-04-29 | $1.00M derived: sum of 2 quarters · filed 2026-04-29 | $1.80M derived: sum of 3 quarters · filed 2026-04-29 | $2.60M derived: sum of 4 quarters · filed 2026-04-29 | |||
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.00M derived: sum of 2 quarters · filed 2026-03-02 | $1.80M derived: sum of 3 quarters · filed 2026-03-02 | $2.90M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $800.00K 10-Q · filed 2025-10-29 | $1.60M derived: sum of 2 quarters · filed 2025-10-29 | $2.70M 10-Q · filed 2025-10-29 | $4.00M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-06-30 | $800.00K 10-Q · filed 2025-07-30 | $1.70M 10-Q · filed 2025-07-30 | $3.20M derived: sum of 3 quarters · filed 2026-03-02 | $4.00M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | $900.00K 10-Q · filed 2025-05-07 | $2.40M derived: sum of 2 quarters · filed 2026-03-02 | $3.20M derived: sum of 3 quarters · filed 2026-03-02 | $4.00M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.30M derived: sum of 2 quarters · filed 2026-03-02 | $3.10M derived: sum of 3 quarters · filed 2026-03-02 | $3.20M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | $800.00K 10-Q · filed 2024-10-30 | $900.00K 10-Q · filed 2023-11-01 | $1.60M derived: sum of 2 quarters · filed 2024-10-30 | $1.70M 10-Q · filed 2024-10-30 | $2.40M 10-Q · filed 2023-11-01 | $3.40M derived: sum of 4 quarters · filed 2025-03-12 | |
| 2023-06-30 | $800.00K 10-Q · filed 2024-07-31 | $1.70M 10-Q · filed 2024-07-31 | $2.60M derived: sum of 3 quarters · filed 2025-03-12 | $3.30M derived: sum of 4 quarters · filed 2025-03-12 | |||
| 2023-03-31 | $900.00K 10-Q · filed 2024-05-01 | $1.80M derived: sum of 2 quarters · filed 2025-03-12 | $2.50M derived: sum of 3 quarters · filed 2025-03-12 | $3.10M derived: sum of 4 quarters · filed 2025-03-12 | |||
| 2022-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $1.60M derived: sum of 2 quarters · filed 2025-03-12 | $2.20M derived: sum of 3 quarters · filed 2025-03-12 | $2.80M 10-K · filed 2025-03-12 | |||
| 2022-09-30 | $700.00K 10-Q · filed 2023-11-01 | $1.30M derived: sum of 2 quarters · filed 2023-11-01 | $1.90M 10-Q · filed 2023-11-01 | $2.60M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-06-30 | $600.00K 10-Q · filed 2023-08-02 | $1.20M 10-Q · filed 2023-08-02 | $1.90M derived: sum of 3 quarters · filed 2024-02-29 | $2.40M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-03-31 | $600.00K 10-Q · filed 2023-05-03 | $1.30M derived: sum of 2 quarters · filed 2024-02-29 | $1.80M derived: sum of 3 quarters · filed 2024-02-29 | $2.20M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2021-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.20M derived: sum of 2 quarters · filed 2024-02-29 | $1.60M derived: sum of 3 quarters · filed 2024-02-29 | $2.20M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $500.00K 10-Q · filed 2022-10-27 | $900.00K derived: sum of 2 quarters · filed 2022-10-27 | $1.50M 10-Q · filed 2022-10-27 | $1.70M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-06-30 | $400.00K 10-Q · filed 2022-08-03 | $500.00K 10-Q · filed 2021-08-05 | $1.20M 10-Q · filed 2022-08-03 | $1.00M 10-Q · filed 2021-08-05 | $1.20M derived: sum of 3 quarters · filed 2023-03-01 | $1.60M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $400.00K 10-Q · filed 2022-05-04 | $800.00K derived: sum of 2 quarters · filed 2023-03-01 | $1.20M derived: sum of 3 quarters · filed 2023-03-01 | $1.60M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $800.00K derived: sum of 2 quarters · filed 2023-03-01 | $1.20M derived: sum of 3 quarters · filed 2023-03-01 | $1.60M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $400.00K 10-Q · filed 2021-11-03 | $800.00K derived: sum of 2 quarters · filed 2021-11-03 | $1.20M 10-Q · filed 2021-11-03 | $1.60M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | $400.00K 10-Q · filed 2021-08-05 | $800.00K 10-Q · filed 2021-08-05 | $1.20M derived: sum of 3 quarters · filed 2022-03-01 | $1.60M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | $400.00K 10-Q · filed 2021-04-29 | $800.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.20M derived: sum of 3 quarters · filed 2022-03-01 | $1.60M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $800.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.20M derived: sum of 3 quarters · filed 2022-03-01 | $1.50M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $400.00K 10-Q · filed 2020-11-05 | $800.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.10M 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | $400.00K 10-Q · filed 2020-08-04 | $700.00K 10-Q · filed 2020-08-04 | |||||
| 2019-03-31 | $300.00K 10-Q · filed 2020-04-30 | ||||||
| 2018-12-31 | $800.00K 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |